Exelixis | EXEL - Market Capitalization


Exelixis reported $16.09B in Market Capitalization this August of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.53B 199M Aug/2026
Akebia Therapeutics USD 427M 297M Dec/2025
Amgen USD 209.65B 14.21B Aug/2026
AstraZeneca USD 178.16B 111.83B Aug/2026
Bayer EUR 49.51B 10.82B Aug/2026
BioMarin Pharmaceutical USD 11.58B 712M Aug/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Cytokinetics USD 8.19B 420M Mar/2026
Eisai JPY 1.3T 102.92B Aug/2026
Eli Lilly USD 1.09T 37.2B Aug/2026
Exelixis USD 16.09B 5.2B Aug/2026
Genmab DKK 20.48B 1.02B Dec/2025
Glaxosmithkline GBP 109.29B 9.36B Mar/2026
Incyte USD 26.84B 4.19B Aug/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
MacroGenics USD 184M 82M Mar/2026
Merck USD 324.18B 6.81B Aug/2026
Nektar Therapeutics USD 12.98B 10.86B Aug/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 240.59B 67.17B Jun/2026
Pfizer USD 143.89B 5.44B Aug/2026
Sanofi EUR 113.52B 3.82B Mar/2026
Takeda JPY 8.2T 809.7B Jun/2026
Ultragenyx Pharmaceutical USD 2.12B 1.16B Aug/2026
Xencor USD 1.22B 325M Aug/2026